Newswise — NEW BRUNSWICK, N.J., Nov. 28, 2023-- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present an extensive array of hematology/oncology data from their clinical research program at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in San Diego, California (and virtually) from December 9-12, 2023. A total of 36 abstracts have been accepted, comprising clinical data and analyses that advance the understanding, treatment, and prognosis of blood cancers such as lymphoma, leukemia, and myeloma. Rutgers Cancer Institute of New Jersey, in partnership with RWJBarnabas Health, is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.
"Our devoted and highly esteemed team of cancer specialists and researchers at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health remain dedicated to pioneering advancements that transform treatments, patient care, and outcomes by leveraging innovation and evolving novel therapies," said Matthew Matasar, MD, MS, Chief of Blood Disorders at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health. "As the leading cancer program in the state, our commitment to advancing oncology care is unwavering. We strive to make a meaningful difference in the lives of those affected by cancer, and through innovative science and research, we can uncover new insights that may transform the landscape of cancer care in the future."
Highlights of the accepted abstracts include the following oral and poster presentations:
- Data from a randomized phase 3 trial conducted by the National Clinical Trials Network evaluating the tolerability and progression-free survival rate of Nivolumab-AVD compared to Bv-AVD in patients aged ≥60 with newly diagnosed advanced-stage Hodgkin lymphoma (AS-HL). The primary endpoint of the study was progression-free survival (PFS), and secondary endpoints included overall survival (OS), event-free survival (EFS), and detailed toxicity and safety events. Response and progression were assessed by investigators using 2014 Lugano Classification.
- Data from a phase 3 trial evaluating the progression-free survival and toxicity with Nivolumab-AVD compared to Bv-AVD in pediatric patients aged ≥12 years with stage 3-4 Classic Hodgkin Lymphoma (cHL). The trial was led by SWOG and conducted by the National Clinical Trials Network. The primary endpoint was progression-free survival (PFS), and secondary endpoints included overall survival (OS), event-free survival (EFS), and safety.
- Evaluation of the A-HIPI model in generating risk groups with input on strengths and limitations for patients with advanced stage classical Hodgkin lymphoma (AS-HL). This prognostic model, developed and validated by the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium, generates the individualized probability of a progression-free survival (PFS) event or death within the first 5 years from diagnosis in patients based on continuous variables.
- Development and validation of the modern-day model, E-HIPI, in the prediction of progression-free survival of early-stage Hodgkin lymphoma (E-HL) within the first five years since diagnosis. The model incorporates detailed individual patient data from international clinical trials and prospective registry data that were standardized, normalized, and harmonized as part of the HoLISTIC Consortium. The primary outcome was progression-free survival (PFS).
- Data from a clinical trial evaluating the feasibility, safety, and efficacy of home-based intravenous administration of trans-retinoic acid (ATRA) and arsenic trioxide in the treatment of Acute Promyelocytic Leukemia (APL). Patients were given the option of receiving at-home treatment through a partnership with Qualitas Specialty Pharmacy and were evaluated for any adverse effects.
The full list of presentations at this year's ASH Annual Meeting and Exposition follows:
Oral Presentations | ||
Abstract and | Title | Presentation Date/Time |
Abstract 181 | Nivolumab-AVD Is Better Tolerated and | Saturday, December 9, 2023: |
Abstract 308 | Improved Survival of R/R Double Hit/Triple | Saturday, December 9, 2023: |
Abstract 382 | Treatment Patterns and Outcomes for Patients | Saturday, December 9, 2023: |
Abstract 497 | Outcomes of Patients with Richter | Sunday, December 10, 2023: |
Abstract 603 | Mosunetuzumab Monotherapy Continues to | Sunday, December 10, 2023: |
Abstract 607 | Results from an Intergroup Randomized | Sunday, December 10, 2023: |
Abstract 610 | Progression-Free Survival (PFS) and Toxicity | Sunday, December 10, 2023: |
Abstract 614 | Mosunetuzumab Monotherapy Demonstrates | Sunday, December 10, 2023: |
Abstract 981 | Pirtobrutinib in Relapsed/Refractory (R/R) | Monday, December 11, 2023: |
Poster Presentations | ||
Abstract and | Title | Presentation Date/Time |
(Session 101) | Congenital Dyserythropoietic Anemia Type | Saturday, December 9, 2023, |
(Session 603) | Acetyl Transferase EP300 Deficiency Leads | Saturday, December 9, 2023, |
(Session 616) | A Phase Ib/II Study Evaluating Navitoclax | Saturday, December 9, 2023, |
(Session 622) | Alterations in Immune Cell Composition | Saturday, December 9, 2023, |
(Session 623) | Pirtobrutinib, a Highly Selective, Non- | Saturday, December 9, 2023, |
(Session 626) | Multicenter Pilot Trial of Intrathecal | Saturday, December 9, 2023, |
(Session 626) | Pirtobrutinib in Richter Transformation: | Saturday, December 9, 2023, |
(Session 627) | Immune Reconstitution and Infection Patterns | Saturday, December 9, 2023, |
(Session 642) | Treatment Effectiveness with Venetoclax- | Saturday, December 9, 2023, |
(Session 703) | CD22 TCR-Engineered T Cells Exert Anti- | Saturday, December 9, 2023, |
(Session 704) | Preliminary Results of Nathali-01: A First-in- | Saturday, December 9, 2023, |
(Session 722) | Outcomes after RIC and Abatacept-Based | Saturday, December 9, 2023, |
(Session 903) | No Place like Home: Home-Based | Saturday, December 9, 2023, |
(Session 905) | Exploration of Language As a Barrier to the | Saturday, December 9, 2023, |
(Session 623) | GLOBRYTE: A Phase III, Open-Label, | Sunday, December 10, 2023, |
(Session 624) | Development and Validation of the Early- | Sunday, December 10, 2023, |
(Session 624) | Identification of Risk Categories from the | Sunday, December 10, 2023, |
(Session 624) | AHOD2131: A Randomized Phase 3 | Sunday, December 10, 2023, |
(Session 652) | Health-Related Quality of Life (HRQoL) | Sunday, December 10, 2023, |
(Session 624) | Age-Based Validation of the Advanced-Stage | Monday, December 11, 2023, |
(Session 626) | Odronextamab Demonstrates Durable | Monday, December 11, 2023, |
(Session 653) | Patterns of Response to 200 Mg | Monday, December 11, 2023, |
(Session 721) | Abatacept-Prophylaxis Based Haploidentical | Monday, December 11, 2023, |
Education Program | ||
N/A | Saturday, December 9, 2023, | |
N/A | Hodgkin Lymphoma Treatment for Older Persons in the Modern Era | Saturday, December 9, 2023, |
N/A | How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023? | Saturday, December 9, 2023: |
Program: Special-Interest Sessions | ||
Session 2 | Sunday, December 10, 2023, | |
RSS